ライフサイエンスコーパス: adoptive immunotherapy

1 ation, useful attributes for T cells used in adoptive immunotherapy.

2 B, either through therapeutic vaccination or adoptive immunotherapy.

3 e clinical application of lymphodepletion to adoptive immunotherapy.

4 eered into tumor-reactive effector cells for adoptive immunotherapy.

5 le to generate tumor-specific Th17 cells for adoptive immunotherapy.

6 o increase the safety and efficacy of cancer adoptive immunotherapy.

7 cells represents a novel approach for cancer adoptive immunotherapy.

8 ier mice of their persistent infection using adoptive immunotherapy.

9 primed in the periphery or delivered during adoptive immunotherapy.

10 cific T cells of desired HLA restriction for adoptive immunotherapy.

11 as a hallmark of successful T-cell-mediated adoptive immunotherapy.

12 s for the improvement of CD8(+) T cell-based adoptive immunotherapy.

13 ced fatalities not typically associated with adoptive immunotherapy.

14 y contribute to the design and monitoring of adoptive immunotherapy.

15 g lymph nodes (TDLN) that are efficacious in adoptive immunotherapy.

16 ity to generate BK-specific T cell lines for adoptive immunotherapy.

17 ulatory T cells and simultaneously performed adoptive immunotherapy.

18 e study of T cell interactions and in T cell adoptive immunotherapy.

19 est that such conversion predicts successful adoptive immunotherapy.

20 d Ag-specific expansion of human T cells for adoptive immunotherapy.

21 une evasion of Fas resistant variants during adoptive immunotherapy.

22 lness of recombinant IL-7 as an adjuvant for adoptive immunotherapy.

23 a significant role in mediating response to adoptive immunotherapy.

24 for the treatment or prevention of PVAN with adoptive immunotherapy.

25 s) or T(reg) cells alone prevented effective adoptive immunotherapy.

26 eening of optimal lymphocyte populations for adoptive immunotherapy.

27 fer can have potential applications in tumor adoptive immunotherapy.

28 erentiation, we evaluated their efficacy for adoptive immunotherapy.

29 present a major factor limiting responses to adoptive immunotherapy.

30 that tolerance might also negatively impact adoptive immunotherapy.

31 ents that demonstrated clinical responses to adoptive immunotherapy.

32 manner to induce leukemia-reactive CTLs for adoptive immunotherapy.

33 es for generating virus-specific T cells for adoptive immunotherapy.

34 ffects, derived from the graft or subsequent adoptive immunotherapy.

35 oietic chimerism can serve as a platform for adoptive immunotherapy.

36 ts, and may be clinically useful for routine adoptive immunotherapy.

37 ase-specific CTLs for clinical approaches to adoptive immunotherapy.

38 s.c. growing tumors on the efficiency of CTL adoptive immunotherapy.

39 ry stimulus has importation implications for adoptive immunotherapy.

40 fied polyclonal T cells that can be used for adoptive immunotherapy.

41 ave been successfully applied clinically for adoptive immunotherapy.

42 have important therapeutic implications for adoptive immunotherapy.

43 ost cell recruitment is a crucial element in adoptive immunotherapy.

44 que for programs exploring the merits of EBV adoptive immunotherapy.

45 colony-stimulating factor, retinoic acid, or adoptive immunotherapy.

46 tion of superior antitumor T cell grafts for adoptive immunotherapy.

47 and have critical implications for effective adoptive immunotherapy.

48 ial application for cellular vaccination and adoptive immunotherapy.

49 lls can be exploited in selected examples of adoptive immunotherapy.

50 t of cervical cancer patients with active or adoptive immunotherapy.

51 s, which could be used for leukemia-specific adoptive immunotherapy.

52 distinct mechanisms operative in successful adoptive immunotherapy.

53 ells that drives differentiation and impairs adoptive immunotherapy.

54 igen-specific T cells ex vivo for autologous adoptive immunotherapy.

55 or cells elicited tumor-reactive T cells for adoptive immunotherapy.

56 expansion of patient-derived CTL for use in adoptive immunotherapy.

57 s may have implications for gene therapy and adoptive immunotherapy.

58 up new possibilities for generating CTLs for adoptive immunotherapy.

59 ti-CD3 and IL-2-mediated tumor regression in adoptive immunotherapy.

60 esting of CML-specific CD4+ T-cell clones in adoptive immunotherapy.

61 ial universal target for selective and broad adoptive immunotherapy.

62 ific CTL could be used for leukemia-specific adoptive immunotherapy.

63 hocytes is the most critical requirement for adoptive immunotherapy.

64 een immune effector cells and tumor cells in adoptive immunotherapy.

65 tive T cells and have broad applications for adoptive immunotherapy.

66 the therapeutic efficacy of both active and adoptive immunotherapy.

67 ualities associated with greater efficacy in adoptive immunotherapy.

68 e the efficacy of vaccination strategies and adoptive immunotherapy.

69 ch to generate Ag-specific T lymphocytes for adoptive immunotherapy.

70 e an unlimited source of functional CTLs for adoptive immunotherapy.

71 numbers of tumor-reactive T lymphocytes for adoptive immunotherapy.

72 ntation is the most potent form of effective adoptive immunotherapy.

73 refore may be the superior subset for use in adoptive immunotherapy.

74 the design of new vaccination strategies and adoptive immunotherapies.

75 a relevant factor in designing hPSC-derived adoptive immunotherapies.

76 the therapeutic potential of both active and adoptive immunotherapies.

77 and lymphoid cell production from hPSCs, for adoptive immunotherapies.

78 eactive CD4(+)-T-cell clones may find use as adoptive immunotherapy against EBV-related lymphoprolife

79 To broaden the clinical application of adoptive immunotherapy against malignancies, investigato

80 Adoptive immunotherapy also has been used for Epstein-Ba

81 itro expansion of tumor-reactive T cells for adoptive immunotherapy also provides a competent memory

82 ly expand tumor antigen-specific T cells for adoptive immunotherapy and for monitoring T cell immunit

83 ion combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail ch

84 Immunomodulation by adoptive immunotherapy and vaccine strategies hold signi

85 lty isolating them in sufficient numbers for adoptive immunotherapy, and the unpredictable persistenc

86 ntioxidants may improve NK cell viability in adoptive immunotherapy applications by stabilizing Sb9.

87 enetic strategy in combating hu cancer by an adoptive immunotherapy approach, which uses the strong x

88 Our data suggest that adoptive immunotherapy approaches to the treatment of ca

89 Adoptive immunotherapy approaches using donor T cells ha

90 vant to the design of T cell-based vaccines, adoptive immunotherapy approaches, or the pharmacologic

91 gnancies may improve the efficacy of current adoptive immunotherapy approaches.

92 nst a localized virus infection in models of adoptive immunotherapy are not well defined.

93 will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.

94 udy was motivated by the potential for using adoptive immunotherapy as either prophylaxis or treatmen

95 capacity, and have potential applications in adoptive immunotherapy as well as for studying the biolo

96 These findings are important for adoptive immunotherapies because they indicate that eDCs

97 studies concluded that lymphopenia augments adoptive immunotherapy by diminishing Tregs and increasi

98 Lymphopenia enhances the effectiveness of adoptive immunotherapy by facilitating expansion of tran

99 This demonstration of adoptive immunotherapy by type II monocytes identifies a

100 Thus, the efficacy of CD8(+) T cells for adoptive immunotherapy can be influenced by opposing dif

101 ransplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, po

102 This is the first demonstration that adoptive immunotherapy can fail as a direct result of pa

103 reover, our data strongly suggest that while adoptive immunotherapy can prevent parasite de-encystati

104 Adoptive immunotherapies composed of T cells engineered

105 To determine the mechanisms by which adoptive immunotherapy could reduce lethality to acute m

106 py (vaccination) required IFN-gamma, whereas adoptive immunotherapy did not.

107 Furthermore, ATV that survived CTL adoptive immunotherapy displayed an even more profound l

108 ts only in immunocompetent mice and enhanced adoptive immunotherapy effects.

109 sts that they are not as effective as TIL in adoptive immunotherapy even when transferred into lympho

110 +) Treg reconstitution in patients receiving adoptive immunotherapy following conditioning regimens d

111 d function might prove critical in improving adoptive immunotherapy for cancer and therapies aimed at

112 ) cells have gained significant attention in adoptive immunotherapy for cancer.

113 es for clinical evaluation in the context of adoptive immunotherapy for hematopoietic stem cell trans

114 urrently being tested in a clinical trial of adoptive immunotherapy for mantle-cell lymphoma.

115 T-cell adoptive immunotherapy for stringent murine tumor models

116 ght be of clinical importance during NK cell adoptive immunotherapy for the treatment of certain canc

117 ination as well as for the development of an adoptive immunotherapy for the treatment of immunocompro

118 The success of adoptive immunotherapy for the treatment of leukemia dep

119 Ex vivo-expanded CD8(+) T cells used for adoptive immunotherapy generally acquire an effector mem

120 Adoptive immunotherapy has been used for relapses after

121 Adoptive immunotherapy has been used to prevent cytomega

122 Adoptive immunotherapy holds promise as a treatment for

123 In adoptive immunotherapy, IL-12- and IL-18-cultured TDLN c

124 novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies.

125 T cells improves the therapeutic outcome of adoptive immunotherapy in a mouse model of disseminated

126 e data support the feasibility of TERT-based adoptive immunotherapy in clinical oncology, highlightin

127 to be a reagent of choice to augment T cell adoptive immunotherapy in clinical trials.

128 logy of lymphopenia" enhance the efficacy of adoptive immunotherapy in lymphoreplete hosts and provid

129 has the potential to accelerate the study of adoptive immunotherapy in preclinical cancer models.

130 We conclude that successful adoptive immunotherapy in this model is mediated through

131 nt of functionally competent Treg cell-based adoptive immunotherapy in transplantation to integrate a

132 he T cell populations that are available for adoptive immunotherapy include both effector memory and

133 Adoptive immunotherapy induces remissions for the majori

134 tion and approaches under evaluation include adoptive immunotherapy, interferon, and small molecules

135 Adoptive immunotherapy involving tumor-specific CD4(+) T

136 Adoptive immunotherapy is a potentially curative therape

137 Adoptive immunotherapy is an appealing approach to cance

138 Adoptive immunotherapy is an approach that involves admi

139 Adoptive immunotherapy is evolving to assume an increasi

140 A major limitation of adoptive immunotherapy is the availability of T cells sp

141 One of the major challenges for adoptive immunotherapy is to be able to effectively targ

142 The goal of adoptive immunotherapy is to target a high number of per

143 In adoptive immunotherapy, ligation of CD3 and CD40 resulte

144 Adoptive immunotherapy may be performed with either auto

145 Adoptive immunotherapy may have therapeutic potential in

146 t patients, we assessed the possibility that adoptive immunotherapy might also effectively treat CAEB

147 e then used as a rationale for developing an adoptive immunotherapy model for treating prostate cance

148 These results indicate that in this adoptive immunotherapy model, neither a direct effect on

149 ntified TDLN B cells as effector cells in an adoptive immunotherapy model.

150 with CD3/CD28 pathways was examined using an adoptive immunotherapy model.

151 portant for optimal tumor regression in this adoptive immunotherapy model.

152 vaccine-draining lymph nodes (TVDLN) in our adoptive immunotherapy model.

153 ly more effective in controlling tumor in an adoptive immunotherapy model.

154 amined the effects of IL-2 and OX-40R mAb on adoptive immunotherapy of advanced tumors.

155 Furthermore, we show that adoptive immunotherapy of an established B16 tumor can b

156 esults provide several avenues for improving adoptive immunotherapy of cancer in patients.

157 enerate chimeric Ag receptors (CARs) for the adoptive immunotherapy of cancer patients with ErbB2-exp

158 Adoptive immunotherapy of cancer requires the generation

159 Successful adoptive immunotherapy of cancer requires the identifica

160 ound that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cel

161 ese findings have important implications for adoptive immunotherapy of cancer, especially in the cont

162 ese findings have important implications for adoptive immunotherapy of cancer, especially in the cont

163 ve as a strategy for both tumor vaccines and adoptive immunotherapy of cancer.

164 ous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer.

165 (IL-2) has been studied extensively for the adoptive immunotherapy of cancer.

166 e the design of clinical trials for specific adoptive immunotherapy of cancer.

167 s for the improvement of CD8(+) T-cell-based adoptive immunotherapy of cancers.

168 These results define a physiologic model of adoptive immunotherapy of CML that will be useful for in

169 inical objective to prevent CMV disease, and adoptive immunotherapy of CMV-specific T cells can be an

170 s expanded ex vivo increased the efficacy of adoptive immunotherapy of disseminated leukemia in mice.

171 In adoptive immunotherapy of established intracranial MCA 2

172 on, and it also serves as a platform for the adoptive immunotherapy of hematologic malignancies using

173 generating sufficient CMV-specific CTLs for adoptive immunotherapy of HLA-A*0201 bone marrow transpl

174 tion of T cells to expand or to engineer for adoptive immunotherapy of human infections or malignancy

175 In adoptive immunotherapy of intracranial (IC) tumors, SEA-

176 eparation of these activities is crucial for adoptive immunotherapy of leukemia without GvH disease.

177 vo generation and expansion for use in human adoptive immunotherapy of leukemia.

178 Therapeutic efficacy of adoptive immunotherapy of malignancies is proportional t

179 ere readily generated and were effective for adoptive immunotherapy of metastasis induced by wild-typ

180 mor-specific T-cell populations suitable for adoptive immunotherapy of multiple myeloma.

181 ntibodies and offer a promising strategy for adoptive immunotherapy of neoplastic diseases.

182 express anti-p53 TCR may be of value for the adoptive immunotherapy of patients with a variety of com

183 ls for research and potentially even for the adoptive immunotherapy of patients with cancer.

184 xpress anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma.

185 cipient origin, the potential application of adoptive immunotherapy of PT-LPD in solid organ recipien

186 and lessons learned from clinical trials of adoptive immunotherapy of viral diseases should facilita

187 Adoptive immunotherapy of virus infection with viral-spe

188 r results further suggest that either T cell adoptive immunotherapy or selected MHC haplotype matchin

189 vidence for synergy between chemotherapy and adoptive immunotherapy or vaccination against self-Ags;

190 by donor type or by use of T-cell depletion, adoptive immunotherapy, or rituximab.

191 Adoptive immunotherapy, or the infusion of lymphocytes,

192 may define methods of successful allogeneic adoptive immunotherapy outside the setting of allogeneic

193 cantly less responsive to eradication by CTL adoptive immunotherapy paradigms as a consequence of inc

194 a cord blood graft that provides a flexible adoptive immunotherapy platform for both children and ad

195 phase 2 study investigated whether Treg-Tcon adoptive immunotherapy prevents posttransplant leukemia

196 oantigen-reactive CD4+ T cells to develop an adoptive immunotherapy protocol that provided local deli

197 In an adoptive immunotherapy protocol, dendritic cells pulsed

198 generation of LMP1-specific CTLs for future adoptive immunotherapy protocols for patients with LMP1-

199 However, adoptive immunotherapy protocols using NK cells have sho

200 In this study, we developed a mouse model of adoptive immunotherapy reflecting immune recognition of

201 d lysis suggest that the pursuit of specific adoptive immunotherapy represents a viable strategy for

202 The efficacy of adoptive immunotherapy requires that transferred T cells

203 Allogeneic adoptive immunotherapy resulted in sustained chimerism,

204 Adoptive immunotherapy retargeting T cells to CD19 via a

205 Analyses of therapeutic effects by the adoptive immunotherapy revealed that the transfer of spl

206 TERT-based adoptive immunotherapy selectively eliminated tumor cell

207 tegies that use such Ags to generate CTL for adoptive immunotherapy should be further developed.

208 s important to maximize the effectiveness of adoptive immunotherapy, some culture conditions may actu

209 Nonetheless, adoptive immunotherapy strategies can be effective, part

210 be used to enhance the antitumor activity of adoptive immunotherapy strategies in human cancer.

211 ntial mechanism by which CY and IL-2 augment adoptive immunotherapy strategies to treat cancer is by

212 Adoptive immunotherapy strategies using ex vivo expanded

213 d in vivo to foster more effective antitumor adoptive immunotherapy strategies.

214 ponses which may have wider consequences for adoptive immunotherapy strategies.

215 ndings have implications for vaccination and adoptive-immunotherapy strategies in this population.

216 suggesting that they are superior for use in adoptive immunotherapy studies.

217 critical component for consistent, long-term adoptive immunotherapy success.

218 Immunotherapy, monoclonal antibodies, and adoptive immunotherapy targeting Epstein Barr virus (EBV

219 cell transplantation provides a platform for adoptive immunotherapy that has clinical potential in th

220 In adoptive immunotherapy, the coadministration of 4-1BB mA

221 If these antileukemia CTL are to be used for adoptive immunotherapy, they must have the capability to

222 might be useful for expansion of T cells for adoptive immunotherapy to allow the inclusion of naive T

223 r lymphocyte infusion (DLI) could be used as adoptive immunotherapy to convert mixed to complete dono

224 Most imaging studies in adoptive immunotherapy to date have focused primarily on

225 ex vivo have the potential to be used as an adoptive immunotherapy to induce allograft tolerance and

226 The potential of adoptive immunotherapy to provide immunity to tumors exp

227 in regulating CD8(+) T-cell tolerance during adoptive immunotherapy to treat leukemia.

228 ed studies that could potentially be used in adoptive immunotherapy to treat melanoma while avoiding

229 ogen-specific memory T cells (referred to as adoptive immunotherapy) to mice burdened with a persiste

230 To evaluate adoptive immunotherapy treatment for B-lineage non-Hodgk

231 s associated with clinical responses in this adoptive immunotherapy trial, suggest that telomere leng

232 lity antigens and predict the feasibility of adoptive immunotherapy trials using Tregs with indirect

233 ay be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen

234 Thus, our findings suggest that adoptive immunotherapy using activated donor NK cells co

235 Adoptive immunotherapy using autologous T cells endowed

236 Adoptive immunotherapy using B-cell-targeted chimeric an

237 Adoptive immunotherapy using chimeric antigen receptor (

238 Adoptive immunotherapy using CTL has provided some clini

239 Thus, an important component of adoptive immunotherapy using CTL is the production of CD

240 Adoptive immunotherapy using cultured T cells holds prom

241 These results suggest that adoptive immunotherapy using cytotoxic T lymphocytes exp

242 The efficacy of adoptive immunotherapy using donor leukocytes to treat P

243 these findings provide proof of concept that adoptive immunotherapy using ex vivo expanded CD38KO NK

244 Adoptive immunotherapy using gammadelta T cells harnesse

245 Adoptive immunotherapy using genetically targeted T cell

246 Adoptive immunotherapy using memory T cells is a highly

247 Adoptive immunotherapy using receptor engineering to ach

248 Adoptive immunotherapy using receptor-modified T lymphoc

249 We present a strategy for adoptive immunotherapy using T-lineage committed lymphoi

250 Adoptive immunotherapy using TCR-engineered PBLs against

251 Adoptive immunotherapy using tumor-infiltrating lymphocy

252 Adoptive immunotherapy utilizing chimeric antigen recept

253 f these cells to be implemented for DC-based adoptive immunotherapy was also considered.

254 The use of this adoptive immunotherapy was associated with no therapy-re

255 replete hosts than in lymphopenic hosts, and adoptive immunotherapy was most effective in lymphoreple

256 lled growth of syngeneic tumors even when an adoptive immunotherapy was not used.

257 To establish a safe platform for adoptive immunotherapy, we first optimized the vector ba

258 Study of this form of adoptive immunotherapy will shed light on different aspe

259 Taken together, our findings show that adoptive immunotherapy with AdE1-LMPpoly vaccine is safe

260 Adoptive immunotherapy with Ag-specific T lymphocytes is

261 gainst leukemic progenitors and suggest that adoptive immunotherapy with allorestricted CTLs directed

262 Adoptive immunotherapy with anti-CD3/IL-2 activated tumo

263 Adoptive immunotherapy with antitumor T cells is a promi

264 Thus, adoptive immunotherapy with autologous "SIV naive" CD4(+

265 Adoptive immunotherapy with autologous and donor-derived

266 Recent studies have indicated that adoptive immunotherapy with autologous antitumor tumor-i

267 We suggest that adoptive immunotherapy with autologous EBV-CTLs may repr

268 In conclusion, adoptive immunotherapy with CD20-specific T cells was we

269 nt study, we tested an alternative approach, adoptive immunotherapy with CD8+ T(M) from donors vaccin

270 linical strategy of TCD followed by targeted adoptive immunotherapy with DLI for those patients with

271 linical strategy of TCD followed by targeted adoptive immunotherapy with DLI in 25 CP CML patients un

272 Adoptive immunotherapy with donor leukocyte infusions (D

273 tioning and that it serves as a platform for adoptive immunotherapy with donor lymphocyte infusions.

274 Adoptive immunotherapy with donor lymphocyte transfusion

275 Adoptive immunotherapy with EBV-specific CTL (EBV-CTL) e

276 Adoptive immunotherapy with EBV-specific cytotoxic lymph

277 take aim at EBV-associated NPC showing that adoptive immunotherapy with EBV-specific T cells expande

278 Adoptive immunotherapy with engineered DC provides a nov

279 ple myeloma patients and have been used with adoptive immunotherapy with gammadelta T cells expressin

280 Adoptive immunotherapy with genetically engineered T cel

281 n, the results of these studies suggest that adoptive immunotherapy with human CMV-specific immune ce

282 ism of immune escape that can be reversed by adoptive immunotherapy with IL-15-transduced NKT cells.

283 These mechanisms blunt adoptive immunotherapy with infused T-cells due to a com

284 the specificity and therapeutic potential of adoptive immunotherapy with NKp30 CAR-expressing T cells

285 Adoptive immunotherapy with peripheral blood-derived vir

286 Adoptive immunotherapy with regulatory T cells (Tregs) i

287 This study also demonstrates that adoptive immunotherapy with small numbers of unirradiate

288 Adoptive immunotherapy with T cells expressing a tumor-s

289 Adoptive immunotherapy with T cells genetically modified

290 -cell responses that promote a GVL effect by adoptive immunotherapy with T-cell clones specific for d

291 After reports that adoptive immunotherapy with T-regulatory cells controls

292 These results provide evidence that adoptive immunotherapy with Tim-3(+) T-bet(+) tumor-spec

293 Thus, adoptive immunotherapy with treated T cells is a novel t

294 Adoptive immunotherapy with tumor-infiltrating lymphocyt

295 Adoptive immunotherapy with tumor-infiltrating lymphocyt

296 The clinical use of adoptive immunotherapy with tumor-reactive T cells to tr

297 Adoptive immunotherapy with tumor-specific T cells has e

298 rus and could, in principle, be a target for adoptive immunotherapy with viral antigen-specific T cel

299 utes to the control of many viral pathogens, adoptive immunotherapy with virus-specific T cells (VSTs

300 ses can be induced in patients via active or adoptive immunotherapy, yet complete tumor eradication o